---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-152351"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:53:06.912727+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Viatris appoints Dr. Rogério Vivaldi Coelho to Board of Directors

## Summary
- Appointment effective June 3, 2024; expands Board from 11 to 12 members.
- Dr. Vivaldi joins the reestablished Science and Technology Committee.
- Former CEO of Sigilon Therapeutics (acquired by Eli Lilly, 2023) and executive at Bioverativ, Spark Therapeutics, and Genzyme.
- Led successful approval of more than 15 orphan products across 20+ countries during Genzyme tenure.
- Will receive standard compensation for non-employee directors; indemnification agreement executed.

## SEC filing metadata
- accession: 0001193125-24-152351
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000119312524152351/0001193125-24-152351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000119312524152351/d832479d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-152351
- JSON: https://secwatch.observer/filing/0001193125-24-152351.json
- Plain text: https://secwatch.observer/filing/0001193125-24-152351.txt

## Key facts
- Executive change
  Rogério Vivaldi Coelho was appointed as Director at Viatris Inc.
  - Action: appointed
  - Role: Director
  source text: On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792044/000119312524152351/0001193125-24-152351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.